Drug Trial Radar · NCT06629584
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 14, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
Conditions
- Malignant Solid Tumors
Interventions
AsciminibDrug
Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major molecular response (MMR) rate by 12 monthsTime frame: at 12 months of therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.